 |
0 Diseases |  |
2 Trials |
|
2 Trials |  |
7 News |  |
- || JNJ-18038683 / J&J
Clinical, Journal: Lack of Efficacy of JNJ-18038683 on Cognitive Impairment in Patients With Stable Bipolar Disorder. (Pubmed Central) - Sep 9, 2024
This study showed no efficacy for the improvement of CIBD or mood symptoms with JNJ-18038683 compared to the placebo.
- ||| JNJ-18038683 / J&J
Trial completion: Testing the Ability of JNJ-18038683 to Improve Cognition and Reduce Depressive Symptoms in Stable Bipolar Patients (clinicaltrials.gov) - Jul 3, 2023
P2, N=60, Completed, Sponsor: Herbert Meltzer
This study showed no efficacy for the improvement of CIBD or mood symptoms with JNJ-18038683 compared to the placebo. Active, not recruiting --> Completed
- | JNJ-18038683 / J&J
Journal: Design and discovery of a high affinity, selective and β-arrestin biased 5-HT Receptor Agonist. (Pubmed Central) - Mar 29, 2022
Although 2a showed about 8 times less activity than 5-HT in the Gs pathway, it showed over 31 times higher activity than 5-HT in the β-arrestin pathway. This constitutes a significant β-arrestin pathway preference and shows 2a to be more potent and more efficacious than the recently published β-arrestin biased 3-(4-chlorophenyl)-1,4,5,6,7,8-hexahydropyrazolo[3,4-d]azepine, the N-debenzylated analog of JNJ18038683 (Compound 7).
- || JNJ-18038683 / J&J
Enrollment closed, Trial completion date: Testing the Ability of JNJ-18038683 to Improve Cognition and Reduce Depressive Symptoms in Stable Bipolar Patients (clinicaltrials.gov) - Jan 19, 2022
P2, N=60, Active, not recruiting, Sponsor: Herbert Meltzer
This constitutes a significant β-arrestin pathway preference and shows 2a to be more potent and more efficacious than the recently published β-arrestin biased 3-(4-chlorophenyl)-1,4,5,6,7,8-hexahydropyrazolo[3,4-d]azepine, the N-debenzylated analog of JNJ18038683 (Compound 7). Recruiting --> Active, not recruiting | Trial completion date: Dec 2021 --> Dec 2022
- || JNJ-18038683 / J&J
Trial completion date, Trial primary completion date: Testing the Ability of JNJ-18038683 to Improve Cognition and Reduce Depressive Symptoms in Stable Bipolar Patients (clinicaltrials.gov) - Nov 10, 2021
P2, N=60, Recruiting, Sponsor: Herbert Meltzer
Recruiting --> Active, not recruiting | Trial completion date: Dec 2021 --> Dec 2022 Trial completion date: Oct 2019 --> Dec 2021 | Trial primary completion date: Jul 2019 --> Sep 2021
- | JNJ-18038683 / J&J
Trial completion date, Trial primary completion date: Imaging 5HT7 Antagonist Effects in Bipolar Disorder (clinicaltrials.gov) - Sep 8, 2021
P=N/A, N=68, Recruiting, Sponsor: King's College London
Trial completion date: Oct 2019 --> Dec 2021 | Trial primary completion date: Jul 2019 --> Sep 2021 Trial completion date: Jul 2020 --> Jun 2022 | Trial primary completion date: May 2020 --> Jun 2022
- Trintellix (vortioxetine) / Lundbeck, Takeda, JNJ-18038683 / J&J
[VIRTUAL] 5-HT7 Receptor and Mood Disorders—Depression, Bipolar and Anxiety: A Systematic Review () - Mar 7, 2021 - Abstract #CINP2021CINP_110;
Being dosed with 5-HT7 antagonists, rodents demonstrated anxiolytic behaviours in experiments. Regarding depression, when being dosed with 5-HT7 antagonists, animals’ reduction of immobility was detected.
- | JNJ-18038683 / J&J
New trial: Imaging 5HT7 Antagonist Effects in Bipolar Disorder (clinicaltrials.gov) - Aug 16, 2018
P=N/A, N=68, Recruiting, Sponsor: King's College London
- || JNJ-18038683 / J&J
Trial completion date, Trial primary completion date: Testing the Ability of JNJ-18038683 to Improve Cognition and Reduce Depressive Symptoms in Stable Bipolar Patients (clinicaltrials.gov) - Apr 27, 2018
P2, N=60, Recruiting, Sponsor: Herbert Meltzer
Regarding depression, when being dosed with 5-HT7 antagonists, animals’ reduction of immobility was detected. Trial completion date: Aug 2017 --> Oct 2019 | Trial primary completion date: Aug 2017 --> Jul 2019
- |||| JNJ-18038683 / J&J
Enrollment open: Testing the Ability of JNJ-18038683 to Improve Cognition and Reduce Depressive Symptoms in Stable Bipolar Patients (clinicaltrials.gov) - Jan 11, 2016
P2, N=60, Recruiting, Sponsor: Herbert Meltzer
Trial completion date: Aug 2017 --> Oct 2019 | Trial primary completion date: Aug 2017 --> Jul 2019 Not yet recruiting --> Recruiting
- ||||| JNJ-18038683 / J&J
New P2 trial: Testing the Ability of JNJ-18038683 to Improve Cognition and Reduce Depressive Symptoms in Stable Bipolar Patients (clinicaltrials.gov) - Jun 9, 2015
P2, N=60, Not yet recruiting, Sponsor: Herbert Meltzer